Lesage Anne sold $81K of PHVS (indirect holdings)

Lesage Anne (Chief Early Development) sold 2,300 indirectly-held shares of Pharvaris N.V. (PHVS) at $35.12 on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lesage Anne
Published Jun 29, 2026, 10:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 10:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
high confidence
Mentioned
$PHVS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (2,300 shares at $35.1242) and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This provides incremental transparency on insider activity but does not introduce new fundamentals, guidance, or regulatory/clinical catalysts.

03

What to watch

Indirect holdings and 10b5-1 structure can obscure true discretion; the modest size ($80.8K) limits interpretive power versus larger, non-10b5-1 transactions.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-29; sale executed 2026-06-25

Background

The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralHigh confidence
Context

SEC Form 4 shows officer Lesage Anne sold 2,300 PHVS shares on 2026-06-25 under a 10b5-1 plan, totaling ~$80.8K.

Expected impact

Low likelihood of sustained price impact; any reaction should be muted unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a disclosed open-market sale with a pre-arranged 10b5-1 plan and modest dollar value, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of reduced conviction; traders may still monitor for a pattern across filings.

Key entities

  • PHVS

    Pharvaris N.V., the company whose insider transaction is disclosed.

  • Lesage Anne

    Chief Early Development; reported an open-market sale of PHVS shares via indirect holdings.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.